Inhibitors of human immunodeficiency virus replication
Compounds of formula I: wherein R 4 , R 6 and R 7 are defined herein, are useful as inhibitors of HIV replication.
1. A compound of the formula (I):
wherein:
R 4 is Het, wherein Het is optionally substituted with 1 to 3 substituents each independently selected from halo, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )haloalkyl, (C 3-7 )cycloalkyl, —OH, —O(C 1-6 )alkyl, —SH, —S(C 1-6 )alkyl, —NH 2 , —NH(C 1-6 )alkyl and —N((C 1-6 )alkyl) 2 , wherein (C 1-6 )alkyl is optionally substituted with hydroxy, cyano or oxo;
R 6 and R 7 are each independently selected from H, halo, (C 1-6 )alkyl and (C 1-6 )haloalkyl; and
Het is a 4- to 7-membered saturated, unsaturated or aromatic heterocycle having 1 to 4 heteroatoms each independently selected from O, N and S, or a 7- to 14-membered saturated, unsaturated or aromatic heteropolycycle having wherever possible 1 to 5 heteroatoms, each independently selected from O, N and S;
or a salt thereof.
2. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is Het optionally substituted with 1 to 2 substituents each independently selected from halo, (C 1-3 )alkyl and —O(C 1-3 )alkyl.
3. A compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 4 is Het optionally substituted with 1 to 2 substituents each independently selected from Cl, F, CH 3 and CH 2 CH 3 wherein Het is a 7- to 14-membered saturated, unsaturated or aromatic heteropolycycle having wherever possible 1 to 2 heteroatoms, each independently selected from O, N and S.
4. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from:
optionally substituted with 1 to 3 substituents each independently selected from halo, (C 1-3 )alkyl and —O(C 1-3 )alkyl.
5. A compound according to claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from:
optionally substituted with 1 to 2 substituents each independently selected from halo, (C 1-3 )alkyl and —O(C 1-3 )alkyl.
6. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is H, F, Cl or (C 1-2 )alkyl.
7. A compound according to claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 6 is H or CH 3 .
8. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is H, F, Cl or CH 3 .
9. A compound according to claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 7 is H or CH 3 .
10. A compound according to claim 1 having the following formula:
wherein R 4 , R 6 and R 7 are defined as:
R 4
R 6
R 7
H
H;
H
H;
H
H;
H
H;
H
H;
H
CH 3 ;
F
H;
H
CH 3 ;
H
CH 3 ;
H
H;
H
H;
H
H;
H
H;
H
CH 3 ;
H
CH 3 ;
CH 3
H;
H
H;
H
H;
H
H;
CH 3
H;
CH 3
H;
H
CH 3 ;
H
CH 3 ;
CH 3
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
H
CH 3 ;
H
H;
H
H;
H
H;
H
CH 3 ;
F
H;
H
CH 3 ;
H
CH 3 ;
H
H;
H
H;
F
H;
Cl
H;
Cl
H;
H
H;
H
H;
H
CH 3 ;
CH 3
CH 3 ;
H
H;
H
H;
F
H;
CH 3
H;
H
H;
H
H;
H
H;
H
H;
H
H;
Cl
H;
Cl
H;
F
H;
Cl
H;
CH 3
H;
H
CH 3 ;
H
H;
H
H;
F
CH 3 ;
F
CH 3 ;
F
CH 3 ;
H
—CH 3 ; or
H
H;
or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 1 having the following formula:
wherein R 4 , R 6 and R 7 are defined as:
R 4
R 6
R 7
H
CH 3 ;
H
CH 3 ;
H
CH 3 ;
H
CH 3 ;
H
CH 3 ;
H
Cl;
H
Cl;
H
H;
H
H;
H
H;
H
H;
H
H;
H
H;
CH 3
H;
Cl
H;
F
H; or
F
CH 3 ;
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
13. A method for treating HIV infection in a host infected by HIV which method comprises administering to such host a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof.
14. A compound according to claim 1 having the following formula:
wherein R 4 , R 6 and R 7 are defined as:
R 4
R 6
R 7
H
H
or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising a compound of formula (I) according to claim 14 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
16. A method for treating HIV infection in a host infected by HIV which method comprises administering to such host a therapeutically effective amount of a compound of formula (I) according to claim 14 or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition according to claim 15 additionally comprising at least one other antiviral agent.
18. A pharmaceutical composition according to claim 17 wherein the at least one other antiviral agent is selected from nucleoside or nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, integrase inhibitors, TAT inhibitors, maturation inhibitors and immunomodulating agents.